In summary, this case report demonstrates that larotrectinib has an unsatisfactory therapeutic effect in NSCLC patients with TPR-NTRK1 fusion and EGFR mutation, probably due to the persistent activation of downstream signaling pathways such as RAF/MEK/ERK. Here, MAP2K7 is linked to non-small cell lung carcinoma.